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Abstract  Melanoma  is  a  common  cutaneous  tumour.  It  is  of  great  importance  due  to  its  increas-
ing incidence  and  aggressive  behaviour,  with  metastasis  to  lymph  nodes  and  internal  organs.
When suspecting  melanoma,  excisional  biopsy  should  be  performed  to  obtain  complete  his-
tological information  in  order  to  determine  the  adverse  factors  such  as  ulceration,  mitosis
rate, and  Breslow  depth,  which  inﬂuence  preoperative  staging  and  provide  data  for  sentinel
lymph biopsy  decision  making.  The  indicated  management  for  melanoma  is  wide  local  excision,
observing recommended  and  well-established  excision  margins,  depending  on  Breslow  depth
and anatomical  location  of  the  tumour.  Therapeutic  lymphadenectomy  is  recommended  for
patients with  clinically  or  radiologically  positive  lymph  nodes.
This article  reviews  surgical  treatment  of  melanoma,  adverse  histological  factors,  sentinel
lymph node  biopsy,  and  radical  lymphadenectomy.
Details  are  presented  on  special  situations  in  which  management  of  melanoma  is  different
due to  the  anatomical  location  (plantar,  subungual,  lentigo  maligna),  or  pregnancy.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).PALABRAS  CLAVE
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Actualización  en  el  tratamiento  quirúrgico  del  melanoma  cutáneo  primario  y
metastásico
Resumen  El  melanoma  es  una  neoplasia  cutánea  común  que  ha  alcanzado  gran  importancia
en las  últimas  décadas  debido  al  aumento  en  su  incidencia  y  a  su  comportamiento  agresivo,  con
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metástasis  ganglionares  y  a  distancia  frecuente.  La  biopsia,  en  caso  de  sospecharse  melanoma,
debe ser  escisional,  con  el  objetivo  de  obtener  información  histológica  completa  y  analizar
factores  de  mal  pronóstico,  como  ulceración,  número  de  mitosis  y  el  Breslow,  que  inﬂuyen
en la  estadiﬁcación  preoperatoria  del  paciente  y  en  la  decisión  de  realizar  biopsia  de  ganglio
centinela  o  no.  La  escisión  local  amplia  es  el  manejo  indicado  para  el  melanoma  con  márgenes
periféricos  de  piel  normal  ya  establecidos  de  acuerdo  al  Breslow  y  a  la  localización  del  tumor.
La linfadenectomía  terapéutica  es  el  tratamiento  recomendado  de  los  pacientes  con  melanoma
que tienen  ganglios  linfáticos  clínica  o  radiológicamente  positivos.
En este  artículo  se  realiza  una  revisión  del  tratamiento  quirúrgico  del  melanoma,  la  toma
adecuada  de  biopsia  de  lesiones  sospechosas,  los  factores  histológicos  adversos,  las  indicaciones
de biopsia  del  ganglio  centinela  y  de  linfadenectomía  radical.  Además  se  revisan  situaciones
especiales  en  las  cuales  el  manejo  del  melanoma  diﬁere  por  su  localización  (acral  plantar,
subungueal,  lentigo  maligno)  o  diagnóstico  durante  el  embarazo.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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lackground
rimary  cutaneous  melanoma  is  one  of  the  most  common
kin  cancers.  It  is  the  ﬁfth  most  common  malignant  neoplasm
n  men  and  the  sixth  most  common  in  women;  it  is  associated
ith  high  morbimortality  due  to  its  aggressive  behaviour,  its
igh  risk  of  regional  and  distant  lymph  node  metastases.1 It
s  estimated  that  in  the  United  States  approximately  76,000
eople  will  have  been  diagnosed  with  melanoma  in  2014,  and
710  deaths  will  be  attributed  to  this  cancer.2 Seventy-ﬁve
ercent  of  skin  cancer-related  deaths  are  due  to  melanoma.
owever,  it  is  believed  that  these  ﬁgures  are  an  underesti-
ation  of  reality,  as  a  considerable  number  of  in  situ  or
uperﬁcial  melanomas  are  not  reported.  The  risk  during  life
f  acquiring  an  in  situ  or  superﬁcial  melanoma  has  consid-
rably  increased,  at  1  in  30  from  1  in  1500  in  1935.3
pidemiology
lthough  melanoma  has  a  peak  of  presentation  between  the
fth  and  sixth  decades  of  life,4 its  incidence  in  people  aged
etween  25  and  29  has  increased  to  become  the  most  com-
on  cancer  in  this  age  group.  Ninety-ﬁve  percent  of  cases
tart  on  the  skin,  the  remainder  originate  from  the  eyes  and
ucosa  (oral,  vagina  or  anus),5 and  from  3%  to  10%  of  people
resent  with  metastatic  disease  with  no  clinically  evident
rimary  lesion.6
iagnostic  approach
f  a  melanoma  is  suspected  a  complete  physical  examina-
ion  of  all  of  the  skin  should  be  made,  including  the  oral  and
nogenital  mucosa,  the  palms  of  the  hands,  and  the  soles
f  the  feet.  There  is  increasing  interest  in  dermatoscopy7
s  a  diagnostic  technique  in  the  study  of  skin  tumours,
specially  pigmented  tumours.  Advanced  digital  computed
maging  techniques  are  also  used.
Once  the  pigmented  lesions  suspicious  of  melanoma  have
een  detected,  an  excisional  biopsy  should  be  performed
margin  of  1--3  mm),8 ideally  with  negative  margins.  On  the
d
g
b
fimbs,  it  should  be  directed  longitudinally  in  order  not  to
ubsequently  alter  the  sentinel  node  result.9
An  appropriate  biopsy  should  enable  the  Breslow’s  depth
o  be  assessed,  since  the  extension  tests  that  are  required,
he  ﬁnal  surgical  margin,  and  the  patient’s  prognosis  will
epend  on  this  Breslow’s  depth,  which  is  the  depth  of  the
elanoma  measured  in  millimetres  from  the  most  superﬁcial
ayer  of  the  epidermis  to  the  deepest  point  of  penetration.
he  greater  the  Breslow  depth  the  poorer  the  patient’s  prog-
osis,  and  the  lower  the  cure  rates.
Excisional  biopsy  is  not  appropriate  on:  the  palms  of  the
ands,  the  soles  of  the  feet,  the  face,  ﬁngers,  subungual
egion,  outer  ear  or  on  very  large  lesions;  and  in  these  cases
t  is  indicated  that  an  incisional  biopsy  is  acceptable,  taking
he  portion  which  has  been  clinically  shown  to  be  deeper.  If
he  incisional  biopsy  does  not  allow  accurate  microstaging
f  the  patient  --  which  is  frequent  due  to  underestimating
he  thickness  of  the  lesion  --  it  is  appropriate  to  repeat  the
rocedure,  and  preferably  go  on  to  perform  an  excisional
iopsy.10
reoperative  staging
hen  the  diagnosis  of  melanoma  has  been  conﬁrmed,  the
atient  needs  to  be  staged.  This  is  determined  by  the  thick-
ess,  the  histological  features  of  the  melanoma  and  the
ocoregional  spread  of  the  disease.  Staging  enables  the  risk
f  lymph  node  and  systemic  metastasis  of  the  melanoma  to
e  evaluated,  which  increases  according  to  the  thickness  of
he  lesions.  The  recommendation,  according  to  NCCN  guide-
ines  (National  Comprehensive  Cancer  Network),  2014,10 is
hat  routine  testing  for  spread  should  not  be  undertaken
n  patients  with  stages  I  and  II,  unless  the  patient  presents
ymptoms  or  signs  of  disease  distant  from  the  primary
umour.  By  contrast,  they  do  stress  that  there  should  be
 complete  physical  examination  of  the  skin,  the  regional
ymphatic  pathways,  and  of  the  nodal  basin.  If  there  are  any
oubts  on  physical  examination  of  the  lymph  nodes,  it  is  sug-
ested  that  an  ultrasound  should  be  performed  of  the  nodal
asin  before  sentinel  node  biopsy.  If  a  suspicious  lesion  is
ound  on  ultrasound,  this  should  be  conﬁrmed  histologically.
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For  stage  III  patients  with  positive  sentinel  nodes  (clini-
cally  negative)  the  panellists  leave  the  decision  to  treating
physician  whether  to  undertake  a  computed  tomography
(CT)  scan  or  a  positron  emissions  scan  (PET/CT).  They  con-
sider  that  histological  conﬁrmation  of  lymph  node  spread  is
appropriate  by  ﬁne  needle  aspiration,  core  needle  biopsy  or
open  biopsy,  and  imaging  studies  for  the  purpose  of  staging,
and  evaluating  speciﬁc  signs  and  symptoms  in  patients  with
stage  III  melanoma  with  clinically  positive  lymph  nodes.  For
patients  with  stage  IV  melanoma  with  distant  metastasis,
the  consensus  recommends  conﬁrming  the  metastasis  histo-
logically,  and  ideally  perform  a  genetic  study  (BRAF  or  c-Kit
mutation)  to  start  targeted  therapy,  lactic  dehydrogenase
(prognostic  marker)  in  addition  to  imaging  studies  (CT  with
or  without  PE/CT),  including  magnetic  resonance  (MRI)  or
contrasted  CT  of  the  central  nervous  system  due  to  the  high
incidence  of  brain  metastasis  in  stage  IV  patients.
Surgical  management
The  surgery  recommended  to  remove  this  tumour,  also
known  as  wide  radical  excision,  is  the  appropriate  way
to  manage  primary  cutaneous  melanoma  in  stages  I--III,
and  including  cases  with  regional  nodal  metastasis.  The
fundamental  objective  is  to  excise  both  the  visible  and
microscopic  tumour,  and  micro-  and  macroscopic  satellites.
This  type  of  surgery  must  meet  2  criteria:  the  resection
of  the  primary  tumour  should  include  a  peripheral  mar-
gin  of  normal  skin  measured  from  the  visible  edge  of  any
residual  pigmentation,  tumour  tissue  or  biopsy  scar,  and  the
deep  margin  of  the  excision  should  extend  to  the  muscular
fascia.11 However,  it  has  not  been  demonstrated  that  includ-
ing  the  muscular  fascia  in  the  resection  is  sufﬁcient  for  the
procedure  to  be  successful.12 The  appropriate  excision  mar-
gins  have  been  widely  investigated  in  randomised  clinical
studies,13,14 and  it  has  been  found  necessary  to  widen  the
margins  as  the  Breslow  depth  of  the  melanoma  increases10
(Table  1).  It  is  considered  unlikely  that  margins  greater  than
2  cm  have  a  signiﬁcant  impact  on  local  recurrence  (12%)
and  the  poor  5-year  survival  rate  (55%)  of  patients  with
melanomas  with  a  Breslow  depth  greater  than  4  mm,  there-
fore  offering  appropriate  management  which,  functionally
and  aesthetically,  is  more  acceptable  for  the  patient.15 The
evidence  shows  that  the  failure  of  the  most  radical  proce-
dures,  such  as  margins  of  3--5  cm  and  limb  amputation,  is  due
to  the  melanoma’s  intrinsic  aggressive  behaviour  and  not
to  inadequate  primary  surgical  management.  Persistence
of  melanoma-positive  margins,  on  histological  examination
of  the  excision,  requires  a  second  excision  to  be  made.  In
Table  1  Excision  margins  according  to  Breslow’s  depth.
Breslow’s  depth  of
the  melanoma  (mm)
Excision  margin
In  situ  5  mm
< 1.00  1  cm  (in  any  anatomical  area)
1.01--2.00 1 cm  (head/neck,  distal  limb)
2 cm  (trunk  and  proximal  limb)
> 2.00 1  cm  (head/neck,  distal  limb)
2 cm  (trunk  and  proximal  limb)
Adapted from NCCN guidelines 2014.4.
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ases  when  it  is  not  possible  to  achieve  tumour-free  negative
argins,  complementary  radiotherapy  has  been  suggested,
hich  has  demonstrated  a  decrease  in  local  recurrence  rates
f  some  histological  types  of  melanoma.16,17
Melanomas  located  on  the  palms  of  the  hands,  soles  of
he  feet,  head,  neck  and  those  which  are  histologically  asso-
iated  with  ulceration,  angiolymphatic  invasion,  satellitosis
r  high  Breslow  depth  have  a  greater  risk  of  local  recurrence
fter  wide  radical  excision.  In  Balch  et  al.  study  of  200118 it
as  demonstrated  that  for  melanomas  of  1--4  mm  thickness,
ocal  recurrence  is  associated  with  high  mortality,  and  that
lceration  on  the  primary  melanoma  is  the  most  important
rognostic  factor  which  should  alert  us  to  the  high  risk  of
ocal  recurrence  and  metastasis.
For  the  majority  of  cases  it  is  recommended  that  the
esidual  defect  should  be  reconstructed  with  primary  clo-
ure  or  a  total  or  partial  thickness  graft.  Flaps  are  only
ndicated  in  cases  where  the  primary  defects  are  too  large
o  perform  the  abovementioned  procedures.  If  a  graft  is
he  best  option  for  reconstructing  a  defect  on  a limb,  it
hould  not  be  collected  from  the  proximal  limb,  as  this  could
otentially  reintroduce  tumour  cells  into  the  reconstructed
ound.
Most  guidelines  recommend  managing  melanomas  with
argins  of  0.5  cm  in  situ.10 However,  applying  these  mar-
ins  has  been  demonstrated  to  be  insufﬁcient  for  managing
entigo  maligna  located  in  the  head  and  neck  due  to  the
rincipally  radial  growth  of  this  melanoma  subtype.  For  this
eason,  it  is  better  approached  if  a  method  with  control  of
he  margin  is  used,  deferring  reconstruction  of  the  defect
ntil  complete  excision  of  the  tumour  has  been  conﬁrmed.19
or  melanoma  in  situ  in  anatomical  areas  other  than  the
ead  and  neck,  it  is  useful  to  make  a  wide  radical  exci-
ion  with  margins  of  0.5--1  cm,  better  cure  rates  have  been
eported  with  margins  of  1  cm,  without  considerable  differ-
nces  in  morbidity.11
pproach to the patient with clinically
egative metastasis-sentinel lymph node
iopsy
fter  surgical  management  of  the  melanoma,  the  next  step
s  to  stage  the  regional  lymph  nodes.  Melanoma  in  situ  has  a
etastatic  potential  that  is  not  signiﬁcant,  as  do  melanomas
ith  a  Breslow  depth  of  less  than  1  mm  which  are  not  asso-
iated  with  other  histological  factors  with  a  poor  prognosis
<  5%).20 For  melanomas  with  a  Breslow  depth  of  between
 and  4  mm  the  risk  of  micrometastasis  to  regional  lymph
odes  is  20--25%,  and  3--5%  for  distant  metastasis,21,22 and
onsidered  as  the  principal  prognostic  factor  for  long-term
urvival  in  patients  with  stage  I  and  III  melanoma.  These
re  not  easily  detectable  with  imaging  techniques  such  as
ltrasound,23 or  even  PET/TC,24 which  is  one  of  the  diag-
ostic  tools  suggested  to  deﬁne  the  presence  or  otherwise
f  metastasis  in  melanoma  patients.  Sentinel  lymph  node
iopsy  is  a  minimally  invasive  procedure  which  is  highly
ccurate  in  detecting  lymph  node  micrometastasis,  and  it
as  replaced  elective  lymphadenectomy  in  staging  patients
ith  clinically  negative  lymph  nodes.  A  randomised  study
evealed  that  sentinel  lymph  node  biopsy  provides  important
rognostic  information,  in  identifying  patients  with  primary
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Oncology  (ASCO-SSO),  is  to  perform  completion  lym-0  
elanomas  with  an  intermediate  or  thick  Breslow  depth,
ith  nodal  metastasis  who  would  beneﬁt  from  immediate
ompletion  lymphadenectomy,  which  prolongs  disease-free
urvival  and  distant  spread  of  the  disease,  in  patients  with
elanomas  of  intermediate  thickness.25 The  ideal  candi-
ate  for  sentinel  lymph  node  biopsy  is  a  patient  with  a
elanoma  of  a  Breslow  depth  of  at  least  1  mm  and  with
o  clinical  or  radiological  regional  lymph  node  metastases.
he  indications  for  sentinel  lymph  node  biopsy  were  recently
roadened,  and  it  is  recommended  in  patients  with  a  Bres-
ow  depth  of  1--4  mm  in  any  anatomical  location,  in  staging
egional  disease  in  patients  with  a  Breslow  >  4  mm,  and
n  patients  with  a  Breslow  depth  of  0.75--1  mm  associated
ith  adverse  histological  factors  such  as  ulceration,  mitotic
ate  >  1,  angiolymphatic  invasion  or  sattelitosis.26 It  is  also
ecommended  that  a  sentinel  lymph  node  biopsy  should  be
outine  in  paediatric  patients  with  a  melanoma  of  a  Bres-
ow  depth  of  1  mm  or  larger,  because  these  patients  have  a
reater  risk  of  lymph  node  metastasis  than  adults,  despite
heir  better  prognosis.  Atypical  melanocytic  nevi  in  children
nd  adolescents  have  a  high  rate  of  positive  sentinel  lymph
odes.  Therefore,  sentinel  lymph  node  biopsy  could  be  indi-
ated  in  paediatric  patients  in  whom  a  melanoma  is  included
s  a  differential  diagnosis.27
The  use  of  sentinel  lymph  node  biopsy  in  some  melanoma
ubtypes  is  controversial;  in  pure  desmoplasic  melanoma,
or  example,  a  low  incidence  of  nodal  metastases  has
een  demonstrated  (0--4%)28,29;  however  in  others,  rates  of
egional  metastases  of  up  to  14%  have  been  found,  and
or  mixed  desmoplasic  melanoma  the  incidence  is  higher
25%)  than  for  pure  desmoplasic  melanoma,  similar  to  that
f  non-desmoplasic  melanoma.30,31 Some  authors,  however,
onsider  that  the  risk  of  lymph  node  metastasis  of  desmo-
lasic  melanoma  is  sufﬁcient  justiﬁcation  for  undertaking  a
entinel  lymph  node  biopsy  if  a  Breslow  depth  of  1  mm  or
ore  is  found  in  these  tumours.10
Despite  the  high  precision  of  sentinel  lymph  node  biopsy
n  detecting  lymph  node  micrometastasis,  there  are  some
ases  where  the  use  of  this  technique  is  suboptimal,  in
atients  who  have  already  undergone  wide  radical  excision
nd  defect  closure,  for  example,  when  lymphogammagra-
hy  has  revealed  more  than  2  lymph  node  drainage  basins,
n  melanomas  near  or  on  the  lymph  node  drainage  basin,
elanomas  of  the  head  and  neck  where  lymphogammag-
aphy  has  mapped  an  intraparotid  sentinel  lymph  node,
hen  there  are  conﬁrmed  distant  lymph  node  metas-
ases,  when  lymphogammagraphy  is  negative,  and  when  life
xpectancy  is  limited,  due  to  advanced  melanoma,  or  other
omorbidities.9
Although  sentinel  lymph  node  biopsy  is  not  a  very  inva-
ive  procedure,  it  is  not  complication-free.  Complications
nclude  those  of  the  surgical  wound  (infections,  dehis-
ence,  etc.)  lymphoedema  (<  5%),  the  formation  of  seroma,
eactions  to  the  contrast  medium  (<1%)  and  false-negative
esults  (5--15%).32
pproach to the patient with clinically
ositive lymph node metastasis
hen  patients  present  with  a  primary  melanoma,  and  with
linically  palpable  lymph  nodes,  lymph  node  metastasis  of
p
n
s
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he  melanoma  should  be  staged  and  conﬁrmed  by  ﬁne  nee-
le  aspiration  biopsy  (FNAB).33 FNAB  is  a fast,  precise  and
linically  useful  technique  for  evaluating  patients  with  a  sus-
ected  metastatic  melanoma.  In  the  event  that  the  tissue
btained  with  FNAB  is  not  sufﬁcient  for  a  diagnosis  or  that
he  resource  is  not  available,  excisional  lymph  node  biopsy
s  suggested.
The  survival  rates  of  patients  who  present  with  clini-
ally  palpable  lymph  node  metastasis  reduce  signiﬁcantly
10--50%),  according  to  the  number  of  lymph  nodes  affected,
he  extent  of  spread  to  the  lymph  nodes,  and  the  Breslow
epth  of  the  primary  melanoma.34
urgical  treatment  of  lymph  node  metastasis
fter  regional  lymph  node  metastasis  of  the  melanoma
as  been  conﬁrmed,  the  standard  treatment  is  radical
ymphadenectomy.  This  in  turn  is  known  by  3  different
erms  according  to  the  method  used  for  diagnosis,  and
hether  or  not  it  has  been  conﬁrmed  histologically.  Thus,
ompletion  lymphadenectomy  refers  to  surgery  after  a
ositive  sentinel  lymph  node  biopsy:  elective  lymphadenec-
omy  when  surgery  is  performed  on  clinically  negative
ymph  node  basins,  and  when  nodal  involvement  has  not
een  conﬁrmed  histologically,  and  ﬁnally,  the  procedure
erformed  on  clinically  positive  lymph  node  basins  after
istological  conﬁrmation,  which  is  known  as  therapeutic
ymphadenectomy.11
Therapeutic  lymphadenectomy  is  indicated  in  all  patients
ith  clinically  evident  lymph  node  metastases,  and  should
ot  be  replaced  by  radiotherapy  or  systemic  adjuvant  ther-
py,  although  they  can  be  used  as  coadjuvant  treatment.35
herapeutic  lymphadenectomy  is  not  indicated  for  patients
n  whom  extensive  distant  metastasis  and/or  large  lymph
ode  metastasis,  ﬁxed  to  adjacent  structures,  has  been  con-
rmed.  These  patients  have  a  poor  prognosis  and  might
eneﬁt  from  other  treatments,  such  as  palliative  radiothe-
apy  or  systemic  therapy.  Elective  lymphadenectomy  is  not
outinely  performed,  and  as  mentioned  above,  has  been
ubstituted  by  sentinel  lymph  node  biopsy.  There  is  some
ontroversy  with  regard  to  the  function  and  indications  of
ompletion  lymphadenectomy  after  positive  sentinel  lymph
ode  biopsy.  To  date,  it  has  not  been  conﬁrmed  that  comple-
ion  lympadenectomy  improves  patient  survival  compared
ith  observation  after  positive  sentinel  lymph  node  biopsy,
r  that  all  patients  with  a  positive  sentinel  lymph  node
iopsy  would  beneﬁt  from  completion  lymphadenectomy,
s  they  do  not  all  develop  clinically  evident  lymph  node
etastasis,  and  sentinel  lymph  node  biopsy  might  have
esected  the  only  focus  of  nodal  metastasis.  Furthermore,
or  the  moment,  there  is  no  evidence  from  patients  with
ositive  sentinel  lymph  node  biopsy  who  do  not  have  at
east  a  5%  probability  of  other  non-sentinel  lymph  node
nvolvement.26
At  present,  the  conclusion  of  the  guidelines  from  the
merican  Society  of  Clinical  Oncology-Society  of  Surgicalhadenectomy  on  all  patients  with  a  positive  sentinel  lymph
ode  biopsy,  and  if  the  patient  refuses  lymphadenectomy,
trict  follow-up  is  recommended  to  enable  the  detection  and
arly  treatment  of  lymph  node  recurrence.26
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Treatment  of  local  recurrence
Locally  recurring  melanoma  is  associated  in  most  cases
with  systemic  metastasis,  which  dramatically  reduces  these
patients’  10  year  survival  (5%).  The  initial  Breslow  thick-
ness  is  the  greatest  prognostic  indicator  of  local  recurrence,
and  death  in  patients  with  melanoma,  associated  with
other  adverse  histological  factors  such  as  ulceration  and
mitosis.9 Clinically  it  presents  as  a  blue  subcutaneous  nod-
ule,  of  variable  size  but  usually  from  2  to  5  cm  in  diameter,
which  commonly  presents  in  the  neighbourhood  of  the  exci-
sion  of  the  primary  melanoma  (satellite  metastasis)  or  en
route  to  the  regional  lymphatic  drainage  basin  (in-transit
metastasis).9 In  these  cases,  diagnosis  should  be  made  by
FNAB  or  with  excisional  biopsy  under  local  anaesthesia.
When  a  diagnosis  of  recurrent  melanoma  is  conﬁrmed,  the
next  step  is  to  undertake  further  imaging  studies  (CT,  MRI
or  PET/CT),  and  sentinel  lymph  node  biopsy,  if  the  patient
is  a  candidate,  for  re-staging,  to  evaluate  symptoms,  and  to
deﬁne  management.10
Ideally,  in  patients  with  recurrent  melanoma  (local,
satellite  and/or  in-transit),  tissue  should  be  taken  for
genetic  analysis  of  the  tumour,  which  is  particularly  impor-
tant  in  order  to  assess  the  use  of  targeted  therapies,  or  plan
their  inclusion  in  a  clinical  study.  If  the  absence  is  conﬁrmed
of  regional  nodal  disease,  surgical  excision  is  recommended
with  negative  margins,  and  primary  closure  of  the  defect,
where  possible.  Patients  with  resectable  in-transit  recur-
rence  might  beneﬁt  from  sentinel  lymph-node  biopsy,  in
addition  to  wide  radical  excision,  and  reconstruction  of  the
defect  with  graft  or  ﬂap.  Although  it  is  still  not  clear  whether
resection  margins  should  be  wide  in  recurrences,  it  is  clear
that  a  margin  of  normal  skin  should  be  left.10
Special clinical situations
There  are  still  questions  as  to  the  correct  management  of
patients  with  primary  melanoma  in  some  clinical  situations,
such  as  subungual  melanoma,  acral  melanoma,  or  the  appro-
priate  management  of  pregnant  patients  with  a  diagnosis  of
melanoma.  However,  expert  recommendations  are  a  tool  on
which  management  of  these  cases  can  be  based.
Subungual  melanoma
This  is  a  rare  variant  of  melanoma  in  the  white  population,
with  a  prevalence  of  3%,  in  contrast  to  its  prevalence  in
black  patients,  of  15--35%.36 The  most  common  location  of
this  melanoma  is  the  ﬁrst  ﬁnger  and  the  ﬁrst  toe  (75%).  It
presents  clinically  as  a  longitudinal  melanonychia,  de  novo
or  pre-existing  with  recent  changes.  Hutchinson’s  sign  --  pig-
mentation  of  the  periungual  skin  --  is  highly  suggestive  of
melanoma  (Fig.  1).  Amelanic  melanoma  presents  atypically
to  conventional  melanoma,  as  an  erythmatose,  frequently
ulcerative  nodule  in  the  subungual  region  associated  with
onycholysis,  and  dystrophy  of  the  nail  plate  with  an  absence
of  pigment.  If  there  are  any  of  these  signs  a  biopsy  should
be  taken  for  histological  conﬁrmation.  Longitudinal  biopsy
which  includes  where  possible  all  the  pigmentation  (exci-
sional),  as  with  other  types  of  melanoma,  is  the  ideal
technique  for  studying  a  lesion  for  which  melanoma  is  the
D
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higure  1  Subungual  melanoma  which  started  as  longitudinal
elanonychia.  Hutchinson’s  sign  is  present.
ifferential  diagnosis.  Biopsy  should  include  tissue  from  the
ail  bed,  and  reach  the  periosteum  in  depth.37
The  margins  for  wide  radical  excision  are  based  on
he  guidelines  according  to  Breslow  thickness,  and  adverse
istological  factors.  If  the  melanoma  is  in  situ, the  recom-
ended  margins  are  5  mm,  including  the  bed  and  proximal
atrix,  and  reconstruction  with  partial  thickness  graft.  The
ost  appropriate  management  of  an  invasive  subungual
elanoma  of  a  lower  limb  is  amputation  at  the  level  of  the
etatarsophalangeal  joint.  However,  for  an  invasive  subun-
ual  melanoma  affecting  an  upper  limb,  amputation  at  the
evel  of  the  joint  distal  to  the  lesion  is  preferred,  using  mar-
ins  of  1  cm,  with  the  objective  of  giving  the  patient  more
onservative  management,  enabling  better  function  of  the
and.38
Indications  for  sentinel  lymph  node  biopsy  in  subungual
elanoma  are  based  on  the  guidelines  for  managing  conven-
ional  melanoma  based  on  the  thickness  of  the  melanoma,
nd  the  presence  or  otherwise  of  palpable  lymph  nodes.26
lantar  acral  melanoma
he  importance  of  this  clinical  subtype  of  melanoma  is  the
oor  prognosis  associated  with  it  due  to  late  diagnosis.39
igh  clinical  suspicion  on  the  part  of  the  treating  physician
s  required  in  addition  to  training  in  dermatoscopy,  as  this
ool  is  very  useful  in  deciding  whether  to  take  a  biopsy  from
 plantar  melanocytic  lesion(Fig.  2).9
Biopsy  in  these  patients  should  be  excisional.  However,
ncisional  biopsy  can  be  used  when  the  lesions  are  very  large.
eﬁnitive  management  is  based  on  the  stage  of  the  dis-
ase  and  the  management  recommended  by  the  established
uidelines  for  melanoma  for  equivalents  in  thickness  and
istology  in  other  skin  locations.10
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PFigure  2  Patient  with  plantar  acral  melanoma.
The  decision  to  perform  a  sentinel  lymph-node  biopsy
s  based  on  the  above-mentioned  ASCO-SSO  indications
ccording  to  the  stage  of  the  melanoma.26 Therapeutic  lym-
hadenectomy  is  recommended  for  primary  melanoma  with
linically  positive  lymph  nodes.
Reconstruction  of  defects  on  the  sole  of  the  foot  depends
n  their  location  on  the  plantar  surface,  the  disease  stage,
omorbidities,  and  the  patient’s  lifestyle.  In  patients  with
efects  in  non-weight  bearing  sites,  sedentary  patients,
omorbidities  and/or  associated  metastatic  disease  a  pri-
ary  closure  of  the  defect  is  preferred  with  either  partial
r  total  skin  graft.  For  defects  on  weight-bearing  sites  on
he  plantar  surface,  the  reconstruction  options  are  rota-
ion  or  advance  skin  ﬂaps  or  free  musculocutaneous  ﬂaps,
referably  performed  by  a  reconstructive  plastic  surgeon.9
entigo  maligna
ith  a  lesion  on  the  face  suggestive  of  lentigo  where  malig-
ant  changes  are  suspected,  a  biopsy  should  be  taken  to
onﬁrm  the  diagnosis.  However,  the  appropriate  method  for
iopsy  is  a  challenge,  as  these  are  usually  lesions  with  poorly
eﬁned  edges,  which  are  large  for  such  an  aesthetically  sen-
itive  area  as  the  face.  According  to  the  guidelines  for  the
anagement  of  melanoma,  the  most  appropriate  method  is
xcisional  biopsy;  incisional  or  shave  biopsy  are  often  sub-
ptimal.  However,  an  acceptable  option  is  a  deep  incisional
iopsy,  or  punch  biopsy  of  the  area  which  is  seen  clinically
o  be  the  deepest.10 Shave  biopsy  can  compromise  com-
lete  histological  evaluation  of  the  tumour,  and  appropriate
reslow’s  depth  measurement,  therefore  we  do  not  use  this
echnique  for  diagnosing  melanoma  in  our  patients.
I
c
r
tM.A.  Zuluaga-Sepúlveda  et  al.
When  a diagnosis  of  lentigo  maligna  has  been  conﬁrmed
he  tumour  is  resected,  5  mm  margins  for  lentigo  maligna
f  the  head  and  neck  are  usually  suboptimal,  therefore
 staged  resection  technique  is  recommended  to  enable
horough  evaluation  of  the  margins.19 On  conﬁrmation  of
he  presence  of  an  invasive  lentigo  maligna,  it  is  staged
ccording  to  Breslow’s  depth.40 Lymph  gammagraphy  with
echnetium  sulphur  colloid  is  used  to  stage  lentigo  maligna
elanoma.  This  substance  replaces  the  blue  stains  which
re  used  routinely,  as  they  are  unnecessary  in  this  site,  and
here  is  a  remote  risk  of  permanent  dyschromia  of  the  skin,
ecrosis  and  anaphylaxis.41 If  micrometastasis  is  conﬁrmed,
 completion  lymphadenectomy  should  be  performed  plus
urface  parotidectomy  if  the  micrometastases  are  in  the
eriparotid  lymph  nodes.9
elanoma  and  pregnancy
elanoma  in  pregnancy  has  a  prevalence  of  up  to  31%,  of
ll  the  cancers  which  present  in  this  condition,42 and  is  a
eoplasm  with  high  morbimorbidity,  and  with  a  not  insignif-
cant  risk  of  metastasis  to  the  placenta  and  the  foetus.  It
s  known  that  pregnancy  does  not  signiﬁcantly  affect  the
ggressivity  of  the  melanoma  in  terms  of  metastasis  and
urvival;  however,  it  is  appropriate  to  be  aware  that  they
an  occur  in  pregnancy,  and  correct  and  fast  management
s  required  in  this  situation.42,43 Biopsy  in  pregnant  patients
ith  a  suspected  melanoma  should  be  excisional  as  in  all
ases,  and  local  anaesthetic  is  recommended  with  lidocaine
ithout  epinephrine.  When  the  diagnosis  has  been  con-
rmed,  staging  can  be  undertaken  safely  with  a chest  X-ray
nd  lactic  dehydrogenase  or  MRI,  or  abdominal  ultrasound
f  the  melanoma  has  a  high  Breslow’s  depth  or  palpable
denopathies.  The  excision  margins  are  the  same  as  those
or  a  woman  who  is  not  pregnant.44 Sentinel  lymph  node
iopsy  is  safe  with  technetium  sulphur  colloid.
onclusions
esions  suspicious  of  melanoma  should  be  biopsied  exci-
ionally  where  possible  in  order  to  enable  the  pathologist
o  report  the  histological  characteristics  of  the  tumour  as
ompletely  as  possible,  which  should  include  the  presence
r  otherwise  of  ulceration,  the  number  of  mitosis,  Bres-
ow’s  depth  and  other  adverse  histological  factors  such  as
lark  level,  the  presence  of  lymphovascular  invasion,  satel-
itosis  and  regression  of  the  melanoma.  Of  these  adverse
istological  factors,  the  most  associated  with  micrometas-
asis  is  ulceration,  followed  by  the  presence  of  one  or
ore  mitoses.  Patients  with  stage  I  and  II  melanoma  do
ot  require  routine  testing.  In  patients  with  regional  lymph
ode  involvement  or  in  stage  III  of  the  disease,  the  rec-
mmendation  is  histological  conﬁrmation  by  ﬁne  needle
spiration  or  open  biopsy,  and  it  is  left  to  the  criteria
f  the  physicians  whether  to  perform  imaging  studies  to
nd  distant  metastases.  Imaging  studies  such  as  CT  and/or
ET,  plus  brain  MRI,  are  indicated  in  patients  with  stageVmelanoma,  and  LDH  level,  which  has  prognostic  signiﬁ-
ance  for  stage  IV  melanomas.  Treatment  for  localised,  and
egionally  metastatic  melanoma  is  essentially  surgical.  The
erm  local  excision  implies  the  use  of  peripheral  margins
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of  1--2  cm  from  any  residual  pigmentation  or  scar,  accord-
ing  to  the  Breslow’s  depth  and  the  anatomical  location
of  the  melanoma.  Sentinel  lymph  node  biopsy  is  a  mini-
mally  invasive  procedure  which  provides  information  on  the
patient’s  prognosis,  and  which  also  identiﬁes  the  patients  for
whom  completion  lymphadenectomy  is  most  useful,  there-
fore  it  has  replaced  scheduled  lymphadenectomy,  which
is  currently  not  recommended  routinely.  The  patients  who
beneﬁt  most  from  sentinel  lymph  node  biopsy  are  those  with
melanomas  of  1--4  mm  with  no  clinical  or  radiological  evi-
dence  of  regional  lymph  node  involvement,  although  the
indications  have  extended  to  further  clinical  scenarios.
Finally,  melanoma  should  be  considered  as  one  of  the
most  aggressive  skin  cancers  due  to  its  high  rates  of  regional,
and  distant  metastasis.  This  cancer  requires  early  diagno-
sis  so  as  to  offer  appropriate  treatment,  and  reduce  the
morbimortality  associated  with  it.
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